Navigation Links
ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia

LOS ANGELES, Jan. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. and Eurogentec S.A. announce a development collaboration to establish a novel system for producing engineered antibody fragments. The two companies will produce ImaginAb's optimized antibody fragments with Eurogentec's high-performance Pichia pastoris expression system. Leveraging Eurogentec's expertise in cGMP manufacturing of recombinant proteins, the collaboration will accelerate the development of ImaginAb's rich pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

"With our rapidly expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase our capacity for fast, reliable protein production," said Dr. Christian Behrenbruch, CEO of ImaginAb. "Eurogentec's Pichia technology has the potential to enable us to take a fresh look at how we do extremely rapid and cost-effective translation into humans with our antibody fragment technology."

Dr. Philippe Cronet, CSO of Eurogentec commented, "We are very committed to exploring new manufacturing strategies for ImaginAb's unique products. Our technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb".

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit

About Eurogentec

Eurogentec is a cGMP accredited Contract Manufacturing Organization (CMO) offering process development and cGMP manufacturing services since 1994. Eurogentec manufactures recombinant proteins, plasmids, vaccines and conjugates in compliance with EU 2003/94/EC and US FDA 21CFR 210 and operates a full-service, state-of-the-art cGMP facility located in Belgium. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan. For more information about Eurogentec, visit

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

SOURCE ImaginAb, Inc.; Eurogentec S.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
2. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
5. DuPont and USDA ARS to Collaborate on New E. coli Test in Beef
6. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
11. febit and TGen Collaborate to Study New DNA Capture Method
Post Your Comments:
(Date:10/12/2015)... CINCINNATI , Oct. 12, 2015 A ... hearing impaired children can predict whether they will develop ... surgery, according to a study in the journal ... --> In the journal,s Oct. 12 ... say their computer program determines how specific regions of ...
(Date:10/12/2015)... Oct. 12, 2015 CorVascular Diagnostics, ... medical technology company that designs and distributes ... it has entered into a collaboration and ... dedicated to producing devices, software and services ... PAD-IQ®, developed and produced by Vasamed, provides ...
(Date:10/12/2015)... PUNE, India , October 12, 2015 /PRNewswire/ ... The Plague - Pipeline Review, H2 2015 ... helps strengthen plague R&D pipelines by identifying new ... products. . --> ... report on Plague pipeline spread across 62 pages, ...
Breaking Medicine Technology:
(Date:10/12/2015)... Angeles, CA (PRWEB) , ... October 12, 2015 ... ... on August 19, 2015, high school aged female athletes, particularly in ... developing potentially sidelining repetitive motion and mechanical overuse injuries than male peers in ...
(Date:10/12/2015)... ... 2015 , ... According to an article published September 27th by ... way to save money on the healthcare needs of patients across the country. Especially ... call visits can often effectively eliminate the need to go in and out of ...
(Date:10/12/2015)... ... October 12, 2015 , ... According to an article ... of San Antonio, Texas recommended that any high-rises in the city limits that do ... going forward. The article explains that it wasn’t until 1982 that the city started ...
(Date:10/12/2015)... ... 12, 2015 , ... The Horizon Foundation for New Jersey has awarded $846,600 ... and enhancing the quality of life in the Garden State. The grants, representing the ... , The charitable arm of Horizon Blue Cross Blue Shield of New Jersey, ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of ... in honor of Breast Cancer Awareness Month. During the month of October, ... a SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. ...
Breaking Medicine News(10 mins):